cd274 antibodyAgricultural BiotechnologyUpdated on Nov 1, 2019 View more like this | Visit SHIRLEY, NY | Contact Bella Smith |
The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1to PD-1, and therefore block the inhibitory function of PD-L1 on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.
